The epidemiology of meningococcal disease and the impact of vaccines.

The epidemiology of meningococcal disease and the impact of vaccines.

Neisseria meningitidis causes endemic meningococcal disease worldwide. Serogroups B and C are responsible for the majority of cases of meningococcal disease in Europe, serogroups B, C and Y cause most disease in the Americas, and serogroups A, C and W135 predominate in Asia and Africa. Polysaccharid...

Bibliografske podrobnosti
Main Authors:	Khatami, A, Pollard, A
Format:	Journal article
Jezik:	English
Izdano:	2010

Podobne knjige/članki

The epidemiology of meningococcal disease and the impact of vaccines (vol 9, pg 285, 2010)
od: Khatami, A, et al.
Izdano: (2011)

The epidemiology of meningococcal disease and the impact of vaccines (Expert Review of Vaccines (2010) 9, 3, (285-298))
od: Khatami, A, et al.
Izdano: (2011)

Global epidemiology of meningococcal disease and vaccine efficacy
od: Pollard, A
Izdano: (2004)

Global epidemiology of meningococcal disease and vaccine efficacy.
od: Pollard, A
Izdano: (2004)

Epidemiology of meningococcal disease in north america.
od: Pollard, A, et al.
Izdano: (2001)

Vaccines for prevention of meningococcal disease.
od: Pollard, A, et al.
Izdano: (2000)

Meningococcal disease and vaccination in North America.
od: Pollard, A, et al.
Izdano: (2001)

Meningococcal vaccines.
od: Rüggeberg, J, et al.
Izdano: (2004)

Meningococcal vaccines.
od: Bethell, D, et al.
Izdano: (2002)

Meningococcal vaccines.
od: Collins, C, et al.
Izdano: (2002)

Vaccine prevention of meningococcal disease, coming soon?
od: Morley, S, et al.
Izdano: (2001)

Vaccine prevention of meningococcal disease, coming soon?
od: Morley, S, et al.
Izdano: (2001)

Meningococcal disease
od: Pollard, A
Izdano: (2018)

Trends in meningococcal disease: challenges for vaccine control when disease is rare
od: Pollard, A, et al.
Izdano: (2017)

Genomic epidemiology of meningococcal vaccine antigens in the United Kingdom
od: Rodrigues, CMC
Izdano: (2018)

Quadrivalent meningococcal conjugate vaccines
od: Pace, D, et al.
Izdano: (2009)

Quadrivalent meningococcal conjugate vaccines.
od: Pace, D, et al.
Izdano: (2009)

Reconsideration of the use of meningococcal polysaccharide vaccine.
od: Granoff, D, et al.
Izdano: (2007)

Meningococcal polysaccharide-protein conjugate vaccines.
od: Snape, MD, et al.
Izdano: (2005)

Towards a global genomic epidemiology of meningococcal disease
od: Retchless, A, et al.
Izdano: (2019)

Meningococcal disease prevention in India.
od: Pollard, A
Izdano: (2014)

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
od: Xie, O, et al.
Izdano: (2013)

Serogroup B meningococcal vaccines-an unfinished story.
od: Sadarangani, M, et al.
Izdano: (2010)

The next chapter for group B meningococcal vaccines
od: Wang, N, et al.
Izdano: (2017)

Group B meningococcal vaccine science and policy
od: Drysdale, SB, et al.
Izdano: (2015)

Epidemic meningococcal disease and travel.
od: Pollard, A, et al.
Izdano: (2002)

Meningococcal disease and healthcare workers.
od: Pollard, A, et al.
Izdano: (1999)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
od: Khatami, A, et al.
Izdano: (2011)

Secondary cases of meningococcal disease.
od: Pollard, A, et al.
Izdano: (1996)

Group B meningococcal vaccine: Recommendations for UK use
od: Pollard, A, et al.
Izdano: (2014)

Group B meningococcal vaccine: recommendations for UK use.
od: Pollard, A, et al.
Izdano: (2014)

Meningococcal disease: clinical presentation and sequelae.
od: Pace, D, et al.
Izdano: (2012)

Meningococcal Disease Prevention in India WESTERN PERSPECTIVE
od: Pollard, A
Izdano: (2014)

Emergency management of meningococcal disease.
od: Pollard, A, et al.
Izdano: (1999)

Erratum: Meningococcal polysaccharide-protein conjugate vaccines (Lancet Infective Diseases (2005) 5 (21-30)
od: Snape, MD, et al.
Izdano: (2005)

Control of invasive meningococcal disease: is it achievable?
od: Marshall, H, et al.
Izdano: (2016)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
od: Lewis, S, et al.
Izdano: (2009)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
od: Pace, D, et al.
Izdano: (2016)

Handbook of meningococcal disease : infection biology, vaccination, clinical management /
od: Frosch, Matthias, et al.
Izdano: (2006)

Emerging clinical experience with vaccines against group B meningococcal disease
od: Wilkins, A, et al.
Izdano: (2017)